Workflow
股价目标
icon
Search documents
Wall Street Analysts See a 26.75% Upside in Archrock Inc. (AROC): Can the Stock Really Move This High?
ZACKS· 2025-05-05 15:01
Shares of Archrock Inc. (AROC) have gained 12.7% over the past four weeks to close the last trading session at $24.56, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $31.13 indicates a potential upside of 26.8%.The average comprises eight short-term price targets ranging from a low of $29 to a high of $33, with a standard deviation of $1.25. While the lowest estimate indicates ...
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
ZACKS· 2025-04-30 14:55
Tarsus Pharmaceuticals, Inc. (TARS) closed the last trading session at $50.90, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $67.13 indicates a 31.9% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $13.74. While the lowest estimate of $41 indicates a 19.5% decline from the current price level, the most optimist ...
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
ZACKS· 2025-04-18 14:56
Group 1 - Corbus Pharmaceuticals (CRBP) closed at $6.03, with a 0.5% gain over the past four weeks, and has a mean price target of $52.11, indicating a potential upside of 764.2% [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $12.31, where the lowest estimate is $35 (480.4% increase) and the highest is $73 (1110.6% increase) [2] - Analysts show strong agreement on CRBP's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for CRBP's current year earnings has increased by 0.1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - CRBP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [10][13]